Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications
Table 2
Baseline characteristics of study subjects with ulcerative proctitis (), by treatment group.
Characteristic
Treatment group
Total ()
Oral 5-ASA ()
Mesalamine suppository ()
Mesalamine enema ()
Age, years
Mean (SD)
51.3 (16.1)
45.5 (15.3)
47.5 (14.9)
47.3 (15.6)
Median
51
45
45
47
Minimum
20
18
18
18
Maximum
89
89
86
89
Frequency distribution by age group, years, (%)
18–24
7 (5.1)
28 (8.6)
5 (6.0)
40 (7.3)
25–34
14 (10.1)
55 (16.8)
12 (14.5)
81 (14.8)
35–44
29 (21.0)
75 (22.9)
22 (26.5)
126 (23.0)
45–54
33 (23.9)
78 (23.9)
17 (20.5)
128 (23.4)
55–64
29 (21.0)
60 (18.3)
15 (18.1)
104 (19.0)
65–74
12 (8.7)
17 (5.2)
7 (8.4)
36 (6.6)
75–84
9 (6.5)
11 (3.4)
4 (4.8)
24 (4.4)
85–94
5 (3.6)
3 (0.9)
1 (1.2)
9 (1.6)
Gender, (%)
Male
77 (55.8)
136 (41.6)
39 (47.0)
252 (46.0)
Female
61 (44.2)
191 (58.4)
44 (53.0)
296 (54.0)
Geographic location, (%)
Northeast
17 (12.3)
42 (12.8)
13 (15.7)
72 (13.1)
North central
49 (35.5)
93 (28.4)
20 (24.1)
162 (29.6)
South
45 (32.6)
145 (44.3)
35 (42.2)
225 (41.1)
West
26 (18.8)
45 (13.8)
15 (18.1)
86 (15.7)
Unknown
1 (0.7)
2 (0.6)
0 (0.0)
3 (0.5)
Principal payer, (%)
Basic/major medical
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
Comprehensive
30 (21.7)
42 (12.8)
13 (15.7)
85 (15.5)
HMO
19 (13.8)
53 (16.2)
11 (13.3)
83 (15.1)
POS, POS with capitation
12 (8.7)
43 (13.1)
11 (13.3)
66 (12.0)
PPO
74 (53.6)
178 (54.4)
46 (55.4)
298 (54.4)
Other
3 (2.2)
11 (3.4)
2 (2.4)
16 (2.9)
Therapy days dispensed on index date, (%)
Oral 5-ASA
31 (15.2)
0 (0.0)
0 (0.0)
8 (15.6)
Mesalamine suppository
0 (0.0)
27 (9.0)
0 (0.0)
16 (14.8)
Mesalamine enema
0 (0.0)
0 (0.0)
22 (8.0)
3 (8.6)
Comorbidities (ICD-9-CM), (%)
Colorectal comorbidities (ICD-9-CM)
Abscess of anal and rectal regions (566)
0 (0.0)
1 (0.3)
0 (0.0)
1 (0.2)
Anal fissure and fistula (565)
3 (2.2)
4 (1.2)
2 (2.4)
9 (1.6)
Benign tumor of the colon (211.3)
15 (10.9)
24 (7.3)
9 (10.8)
48 (8.8)
Benign tumor of the rectum and anal canal (211.4)
1 (0.7)
5 (1.5)
1 (1.2)
7 (1.3)
Diverticula of intestine (562)
10 (7.2)
12 (3.7)
6 (7.2)
28 (5.1)
Functional digestive disorders, not elsewhere classified (564)
15 (10.9)
36 (11.0)
6 (7.2)
57 (10.4)
Malignant neoplasm of colon (153)
0 (0.0)
0 (0.0)
1 (1.2)
1 (0.2)
Other and unspecified noninfectious gastroenteritis and colitis (558)
54 (39.1)
56 (17.1)
25 (30.1)
135 (24.6)
Vascular insufficiency of intestine (557)
2 (1.4)
0 (0.0)
0 (0.0)
2 (0.4)
Other digestive comorbidities (ICD-9-CM)
Chronic liver disease and cirrhosis (571)
1 (0.7)
2 (0.6)
1 (1.2)
4 (0.7)
Diseases of esophagus (530)
13 (9.4)
30 (9.2)
9 (10.8)
52 (9.5)
Disease of pancreas (577)
0 (0.0)
2 (0.6)
0 (0.0)
2 (0.4)
Duodenal ulcer (532)
0 (0.0)
1 (0.3)
0 (0.0)
1 (0.2)
Gastric ulcer (531)
0 (0.0)
1 (0.3)
1 (1.2)
2 (0.4)
Common nondigestive comorbidities (ICD-9-CM)
Asthma (493)
5 (3.6)
7 (2.1)
2 (2.4)
14 (2.6)
Atherosclerosis (440)
1 (0.7)
2 (0.6)
0 (0.0)
3 (0.5)
Chronic bronchitis (491)
2 (1.4)
0 (0.0)
0 (0.0)
2 (0.4)
Diabetes mellitus (250)
15 (10.9)
16 (4.9)
6 (7.2)
37 (6.8)
Essential hypertension (401)
29 (21.0)
52 (15.9)
17 (20.5)
98 (17.9)
Iron deficiency anemias (280)
10 (7.2)
5 (1.5)
2 (2.4)
17 (3.1)
Ischemic heart disease (410–414)
13 (9.4)
12 (3.7)
4 (4.8)
29 (5.3)
HMO: health maintenance organization. Oral 5-ASA: oral 5-aminosalicylate. POS: point of service. PPO: preferred provider organization.
